Borchmann, Peter (2014). Early Intensification Treatment Approach in Advanced-stage Hodgkin Lymphoma. Hematol. Oncol. Clin. North Am., 28 (1). S. 65 - 76. PHILADELPHIA: W B SAUNDERS CO-ELSEVIER INC. ISSN 1558-1977

Full text not available from this repository.

Abstract

The key question in advanced-stage Hodgkin lymphoma for many years now has been, should intensified chemotherapy be applied upfront or be reserved for relapsing patients. The early intensification approach with BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) aims at curing patients with first-line chemotherapy definitely. The added toxicity of this approach as compared to less intensive regimens as ABDV (doxorubicin, bleomycin, dacarbazine, vinblastine) is mainly restricted to acute haematotoxicity and gonadal damage. However, regarding efficacy, there is a meaningful survival-benefit over ABVD (10% at 5 years) and the intensified first-line treatment strategy is thus rightly regarded as standard of care.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Borchmann, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-447976
DOI: 10.1016/j.hoc.2013.10.002
Journal or Publication Title: Hematol. Oncol. Clin. North Am.
Volume: 28
Number: 1
Page Range: S. 65 - 76
Date: 2014
Publisher: W B SAUNDERS CO-ELSEVIER INC
Place of Publication: PHILADELPHIA
ISSN: 1558-1977
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
COLONY-STIMULATING FACTOR; ELDERLY-PATIENTS; COPP-ABVD; US FACE; CHEMOTHERAPY; DISEASE; BEACOPP; TRIAL; ADRIAMYCIN; BLEOMYCINMultiple languages
Oncology; HematologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/44797

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item